Captrust Financial Advisors Lowers Holdings in Stryker Co. (NYSE:SYK)

Captrust Financial Advisors reduced its position in shares of Stryker Co. (NYSE:SYK) by 4.3% in the third quarter, Holdings Channel reports. The firm owned 35,964 shares of the medical technology company’s stock after selling 1,611 shares during the quarter. Captrust Financial Advisors’ holdings in Stryker were worth $12,992,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Wealth Enhancement Advisory Services LLC increased its position in shares of Stryker by 78.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock valued at $45,260,000 after acquiring an additional 58,673 shares in the last quarter. OFI Invest Asset Management boosted its stake in Stryker by 3,210.9% during the 2nd quarter. OFI Invest Asset Management now owns 3,344 shares of the medical technology company’s stock valued at $1,062,000 after purchasing an additional 3,243 shares during the last quarter. Baltimore Washington Financial Advisors Inc. increased its holdings in shares of Stryker by 2.4% in the 3rd quarter. Baltimore Washington Financial Advisors Inc. now owns 66,681 shares of the medical technology company’s stock worth $24,089,000 after purchasing an additional 1,554 shares in the last quarter. Sivik Global Healthcare LLC raised its stake in shares of Stryker by 8.0% in the third quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company’s stock worth $9,754,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in shares of Stryker by 2.7% during the second quarter. Envestnet Asset Management Inc. now owns 618,041 shares of the medical technology company’s stock valued at $210,289,000 after purchasing an additional 16,504 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP M Kathryn Fink sold 7,347 shares of the stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $366.98, for a total transaction of $2,696,202.06. Following the completion of the transaction, the vice president now directly owns 10,042 shares of the company’s stock, valued at approximately $3,685,213.16. The trade was a 42.25 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 66,781 shares of company stock valued at $24,612,275. 5.90% of the stock is currently owned by insiders.

Stryker Stock Up 1.0 %

NYSE SYK opened at $392.15 on Monday. The stock has a market cap of $149.50 billion, a PE ratio of 42.03, a P/E/G ratio of 2.96 and a beta of 0.91. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. Stryker Co. has a 12 month low of $285.79 and a 12 month high of $398.20. The stock’s 50 day moving average is $368.51 and its 200 day moving average is $351.74.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker’s quarterly revenue was up 11.9% on a year-over-year basis. During the same period last year, the company posted $2.46 earnings per share. Research analysts predict that Stryker Co. will post 12.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. UBS Group upped their target price on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research note on Wednesday, October 30th. Evercore ISI increased their price objective on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. Piper Sandler reaffirmed an “overweight” rating and issued a $420.00 target price (up previously from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Finally, Citigroup lifted their price objective on Stryker from $406.00 to $411.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus price target of $393.65.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.